COVID-19 and Heart Damage: Latest StudiesCOVID-19 and Heart Damage: Latest StudiesAtcor_Logo_30hCOVID-19 and Heart Damage: Latest Studies
  • Solutions
    • Clinical Trials
      • Overview
      • Hypertension
      • Renal Disease
      • Heart Failure
      • Cognitive Impairment
      • Diabetes
      • COPD
    • Research
    • Clinical Practice
  • Technology
    • NcBP
    • SphygmoCor®
    • Oscar 2 With SphygmoCor® Inside
    • Arty Heart Health – TicWatch GTH Pro
      • Arty Heart Health Platform
      • Watching Your Heart Health
      • Visit GTH Pro
      • Buy GTH Pro Now
  • Resources
    • Publications
    • Case Studies
    • Newsletter
    • Videos
    • Webinars
    • White Papers
  • Customers
    • Register
    • Customer Log-in
  • About
    • Overview
    • Team
    • Advisory Board
    • Intellectual Property
    • News & Media
    • ASX Announcements
  • Blog
  • Contact
    • Contact Us
    • Technical support

COVID-19 and Heart Damage: Latest Studies

Published by Bobby Stutz - ATCOR Director of Pharmaceutical Markets on August 31, 2020

As researchers, clinicians, and the general public struggle to understand the nature and direction of COVID-19, new clues and insights are emerging all the time. Case in point: two new studies from Germany and appearing in JAMA Cardiology point to permanent heart damage in COVID-19 patients, even among individuals who were healthy before they recovered from their initial symptoms.

Although COVID-19 clearly attacks the respiratory tract, its cardiac involvement appears to be significant as well. The two new studies follow numerous others that have explored the cardiac health/COVID-19 connection.

Study 1

In the first of the new reports, the authors evaluated cardiac magnetic resonance (CMR) images from 100 COVID-19 patients ages 45 to 53 and compared them with CMR images of similar individuals (controls: 50 healthy and 57 risk-factor matched) who did not have the disease. One third of the patients had been hospitalized for COVID while the remaining patients recovered at home. (1)

Slightly more than three-quarters (78 patients) who recovered from COVID-19 showed structural changes to their hearts, even two months after recovery. All but two of them demonstrated biomarkers usually seen in individuals who have had a heart attack, and 60 had myocarditis.

More specifically, compared with controls, patients who recovered from COVID-19 had:

  • Lower left ventricular ejection fraction
  • Higher left ventricle volumes
  • Greater left ventricle mass
  • Raised myocardial native T1 and T2

According to the study’s co-author, Dr. Valentina Puntmann, a cardiologist, clinical pharmacologist, and consultant physician at University Hospital Frankfurt, Germany, she, her fellow researchers, and the patients “were both surprised by the intensity and prevalence of these findings.” (2)

Study 2

This study involved reviewing the autopsy reports from 39 COVID-19 patients ages 78 to 89. Overall, the SARS-CoV-2 virus was documented in 24 (61.5%) of the patients, while the viral load was greater than 1000 copies per microgram in 16 (41.0%). (3)

Study co-author and cardiologist Dirk Westermann of the University Heart and Vascular Centre in Hamburg noted that “We see signs of viral replication in those that are heavily infected. At this point in time, however, he explained that “we don’t know the long-term consequences of the changes in gene expression,” emphasizing that “it’s obviously not good to have that increased level of inflammation.”(2)

Bottom line

Cardiac involvement in COVID-19 patients, including those who are relatively healthy prior to infection, is an emerging concern and highlights the need for clinicians to evaluate the cardiovascular risk factors of all their patients. Use of state-of-the-art diagnostic techniques that gather information on central arterial blood pressure, arterial inflammation, arterial stiffness, and pulse wave reflections, among others, will be critical as we tackle the COVID-19 pandemic and is consequences.

References

  1. Puntmann VO et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiology2020 Jul 27
  2. Mazziotta J. Three-quarters of recovered coronavirus patients have heart damage months later, study finds. People.com 2020 Jul 28
  3. Lindner D et al. Association of cardiac infection with SARS-CoV-2 in confirmed COVID-19 autopsy cases. JAMA Cardiology 2020 Jul 27

Share

Related posts

Covid 19 and blood cells
March 20, 2023

How Cardiovascular Health Impacts Covid Outcomes


Read more
Man sleeping
March 17, 2023

How Sleep Affects Cardiovascular Health


Read more
March 17, 2023

The Importance of Central Blood Pressure


Read more
Sign up for our VITALITY newsletter

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: ATCOR, 184 Shuman Blvd, Naperville, IL, 60563, http://www.atcormedical.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

You can unsubscribe at any time

Subscribe

AtCor Icon

Solutions
Clinical Trials
 - Hypertension
 - Renal Disease
 - Heart Failure
 - Cognitive Impairment
 - Diabetes
 - COPD
Research
Clinical Practice

Technology
NcBP
SphygmoCor®
Oscar 2 With SphygmoCor® Inside

Resources
Publications
Case Studies
Newsletter
Videos
Webinars
White Papers
About
Overview
Team
Advisory Board
Intellectual Property
News & Media
ASX Announcements

Blog

Privacy Policy
Disclaimer
Acceptable Use Policy
Contact Us
Technical Support
Contact Us


+1 (630) 228-8871

[email protected]

The Cardiex group of companies is pleased to be a member of these esteemed professional organizations.
Copyright © 2023 ATCOR. All Rights Reserved.

    Software Downloads – Quick Descriptions

    XCEL Installation Package V1.3

    XCEL V1.3 is the latest ATCOR release of the base XCEL software.  It is a required installation for all clinical practice, academic research, and clinical trials.


    XCEL Secure Data Option Installation Package 

    XCEL Secure Data Option software enables Part11 readiness for clinical practice, academic research, and clinical trials.  Prior to install, confirm that the XCEL V1.3 software is fully installed prior to the XCEL Secure Installation Package. Contact Us for more information.


    Calibration Kit Software

    For customers who have the XCEL calibration kit, this software is used for the annual calibration of the SphygmoCor XCEL.  The SphygmoCor XCEL Calibration Kit, sold separately, is required for this calibration procedure.